Lipocine Inc. announced on November 10, 2026, that the first participant has been dosed in the BLOOM Phase 3 study evaluating LPCN 1154 for postpartum depression (PPD). The company filed an -K with the SEC to report this event.
LPCN 1154 is an investigational oral formulation of brexanolone, chemically identical to the neuroactive steroid allopregnanolone. The treatment is being developed as a 48-hour oral course intended for at-home use. The BLOOM study is a placebo-controlled outpatient trial designed to evaluate the efficacy and safety of the drug.
The study is expected to enroll approximately 120 participants. Topline results are anticipated in the second half of 2027. The trial incorporates design and operational measures intended to improve data quality and reduce placebo response. These measures include third-party support for site selection, geographic diversity, limiting the number of participants per site, and centralized rating for screening and eligibility.
According to the company, feedback from the U.S. Food and Drug Administration (FDA) indicated that an NDA submission package presented to the agency appears complete to support a 505(b)(2) pathway, with the exception of the need for a single positive and well-controlled Phase 3 trial. Lipocine noted that safety outcomes and exploratory findings from a prior Phase 3 trial support further evaluation of LPCN 1154, although that prior trial did not meet its primary endpoint in the full analysis set.
The company stated that the BLOOM study design incorporates lessons from the prior trial and FDA feedback, including strengthened site selection and eligibility assessments. However, the company emphasized that these measures do not establish efficacy or assure a successful outcome.
